| Moderator: |
Loïc Kubitza, Director, Pharmaceuticals & Life Sciences, Price Waterhouse Coopers |
|
| 08.30 |
Registration |
|
SESSION 1 |
| 09.00 |
Welcome
Nick Archer HMA, British Ambassador to Denmark
|
|
| 09.10 |
KEYNOTE: An introduction to Companion diagnostics and Personalised Medicine in Cancer
Jan Trøst Jørgensen
Director of Medical Affairs, CMC Contrast AB and External Lecturer, Faculty of Pharmaceutical Sciences, Univ. of Copenhagen
|
|
| 09.30 |
KEYNOTE: Moving towards personalised healthcare
Loïc Kubitza, Director, Pharmaceuticals & Life Sciences, Price Waterhouse Coopers
|
|
| 09.50 |
COMPANY PRESENTATION FINLAND: From treatments to trials: Personalisation from day one
Pekka Simula, CEO, Oncos Therapeutics
|
|
| 10.00 |
KEYNOTE: Diagnostics Solutions for Personalised Medicine
Dr Stephen Little, VP Personalised Medicine, Qiagen Manchester Ltd
|
|
| 10:20 |
Networking Coffee Break |
|
SESSION 2 |
| 11:00 |
KEYNOTE: Partnering in the Development of Targeted Oncology Therapies
Cecilia Schott, PharmD MBA, Business Development Director, Personalized Healthcare, AstraZeneca Pharmaceuticals LP
|
|
| 11.20 |
COMPANY PRESENTATION DENMARK:How does drug-companion diagnostics co-development add value to the development of oncology pharmaceuticals?
Henrik Winther, Director of Immunohistology and Companion Diagnostics, Dako A/S
|
|
| 11.30 |
COMPANY PRESENTATION UK: Development and provision of companion diagnostic services to the pharmaceutical and healthcare industries
Berwyn Clarke, Chief Scientific and Development Officer, Lab 21 Ltd
|
|
| 11.40 |
COMPANY PRESENTATION SWEDEN: Quantifying protein-protein interactions in native cells and tissue samples - a new opportunity for Companion Diagnostics
Mats Gullberg, Chief Technology Officer, Olink Bioscience
|
|
| 11.50 |
Networking Lunch |
| 12.00 |
One to One Pre Booked Partnering
|
|
SESSION 3 |
| 14.00 |
KEYNOTE:Development of Targeted Oncology Therapies at the Institute of Cancer Research, UK
Dr. Jonathan Beech, Business Development Manager, The Institute of Cancer Research
|
|
| 14.20 |
COMPANY PRESENTATION DENMARK: Locked Nucleic Acids: Enabling MicroRNA Cancer Diagnostics
Søren Morgenthaler Echwald, Vice President Business Development, Exiqon A/S
|
|
| 14.30 |
Networking coffee break |
|
| 15.00 |
KEYNOTE:The molecular basis of chemosensitivity to cytotoxic agents
Professor Ian A Cree, Director, Translational Oncology Research Centre, Portsmouth Hospitals NHS Trust / University of Portsmouth
|
|
| 15.20 |
COMPANY PRESENTATION NORWAY:DiaGenic - Norway's most innovative company 2009
Eric Christensen, CEO, Diagenic ASA
|
|
| 15.30 |
COMPANY PRESENTATION UK:The development of multigene prognostic and predictive tests for cancer management
Dr Austin Tanney, Scientific Liason officer, Almac Diagnostics
|
|
| 15.40 |
COMPANY PRESENTATION SWEDEN:Estrogen receptor B selective agonists: First in class therapy for treatment of intra-hepatic cholangiocarcinoma?
Stefan Nilsson, PhD, Associate Professor, Senior Project Manager, Karo Bio AB
|
| 15.50 |
COMPANY PRESENTATION ICELAND:Nationwide approach to chemo-sensitivity testing
Finnbogi Thormodsson, University of Iceland
|
|
| 16.00 |
Networking Reception |
|
| 17.00 |
End |
To find out more about the Conference, please contact the organisers by emailing Christina Bergstrand, or call +46 86713065
